Detail akcie Anixa Bioscincs Rg online

Business Summary: Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Financial Summary: BRIEF: For the fiscal year ended 31 October 2025, Anixa Biosciences Inc revenues was not reported. Net loss decreased 13% to $10.9M. Lower net loss reflects Research and development expenses decrease of 23% to $3.5M (expense), Stock-based Compensation in SGA decrease of 23% to $2.3M (expense), Stock-based Compensation in R&D decrease of 16% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.34.